BSO-07

CAT: 0804-HY-162886Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-162886Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BSO-07 is a ROS/JNK activator with significant anticancer effects, having an IC50 value of 24.81 μM against human breast cancer (BC) cells. BSO-07 induces apoptosis (Apoptosis) and paraptosis by activating JNK and increasing ROS levels, including enhancing the expression of apoptosis-associated proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, while decreasing the levels of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Survivin. BSO-07 holds promise for research in the field of breast cancer[1].
UNSPSC
12352101
Target
JNK; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bso-07.html
Smiles
ClC1=CC=C(N2CCN(CC3=NO[C@@](CCC4)([H])[C@@]4([H])[C@H]3C5=CC=CC=C5)CC2)C(F)=C1
Molecular Formula
C24H27ClFN3O
Molecular Weight
427.94
References & Citations
[1]Kim NY, et al. Oxazine drug-seed induces paraptosis and apoptosis through reactive oxygen species/JNK pathway in human breast cancer cells. Transl Oncol. 2024 Nov;49:102101.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-106156Allotrap 07
HY-108003-01MM 07
HY-144308RMS-07
HY-149495CP-07
HY-125158HOI-07
HY-172590LZ-07
HY-163912JZD-07
HY-131031-01KCC-07
HY-100494-01SH5-07
HY-105315AFP-07

Alternative Products

CatalogName
MF-0110238-01BSO-07
S9728-5mgBSO
STJ501223Anti-07/02/07
C18069SH5-07 (SH-5-07)
MF-0046203MM 07
MF-0062154-01AFP-07
MF-0094290-01KCC-07
MF-0018047-01SH5-07
MBS5812272ADA-07
MBS5774600TBZ-07

Popular Products